Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Since cord blood transplantation (CBT) has been associated with high graft-versus-leukemia effects and a low incidence of chronic graft-versus-host disease (GVHD), we hypothesized that long-term outcomes might be better in CBT patients than in those given grafts from unrelated donors (UD). Therefore, we performed a landmark study comparing long-term outcomes in acute myeloid leukemia (AML) patients alive and disease-free 2 years after transplantation who received grafts from either CBT or UD. A total of 364 CBT recipients, 2648 UD 10/10 patients and 681 patients given grafts from UD 9/10 were included. Median follow-up was 6.0 years. Five-year leukemia-free survival (LFS) from transplantation was 86% in CBT patients, 84% in UD 10/10 patients (P = 0.36) and 84% in UD 9/10 patients (P = 0.86). On multivariate analysis, donor type had no impact on LFS. Similarly, no impact of donor type was observed on relapse incidence or non-relapse mortality. Factors associated with poorer LFS on multivariate analysis included higher age at transplantation (P < 0.001), male gender (P < 0.001), second complete remission (CR2) versus CR1 (P = 0.05), secondary AML (P = 0.01), antecedent of chronic GVHD (P < 0.001) and poor-risk cytogenetics (P = 0.01). In conclusion, our study shows that long-term outcome for AML patients in CR two years after transplantation is not impacted by donor type.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Bone Marrow Transplantation |
Vol/bind | 56 |
Udgave nummer | 11 |
Sider (fra-til) | 2742-2748 |
Antal sider | 7 |
ISSN | 0268-3369 |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
FB has received travel grants and/or speaker honoraria from Celgene, AbbVie, Novartis, Pfizer, and Sanofi. HCR received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck. HCR received research funding from Gilead Pharmaceuticals. HCR is a co-founder of CDL Therapeutics GmbH. The other authors declare that they have no relevant conflict of interest in relation to this study.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
ID: 304460240